Björklund Pharma

  • Home
  • Company
  • Science & Innovation
  • Publications
  • Media
  • Contact
    • Contact Form

Company

Björklund Pharma AS is an early-stage biopharmaceutical company owned by G. Björklund, MD. Its focused strategy is designing, researching, and developing biopharmaceuticals targeted at diseases with unmet medical needs. The company is specialized in biofactors. I.e., substances the body requires for its normal, physiologic functioning and/or health-beneficial and/or disease-preventive biological activities. Dietary biofactors include vitamins, pro-vitamins, minerals, trace elements, enzymes, peptides, amino acids, fatty acids, and phytochemicals.

Contact

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment

RSS CONEM Autism Research

  • Zinc, Copper, and Autism Spectrum Disorder
  • Digestive Enzyme Therapy: A Possible Option in Autism Spectrum Disorder
  • Vitamin D Deficiency Correlates with Severity of Autism and Shows Improvement with Supplementation
  • ADHD, Autism, and Phenylketonuria
  • Serum Zinc and Copper Levels in Autistic Children

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2023 Björklund Pharma AS